174 related articles for article (PubMed ID: 3111667)
1. Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth.
Balsan S; Stéru D; Bourdeau A; Grimberg R; Lenoir G
Calcif Tissue Int; 1987 Jun; 40(6):303-9. PubMed ID: 3111667
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation.
Aicardi G; Benso L; Vignolo M; Terragna A; Verrina E; Cordone G; Coppo R; Sernia O; Sardella ML; Di Battista E
Br J Rheumatol; 1993 May; 32 Suppl 2():39-43. PubMed ID: 8495279
[TBL] [Abstract][Full Text] [Related]
3. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans.
Gennari C; Imbimbo B; Montagnani M; Bernini M; Nardi P; Avioli LV
Calcif Tissue Int; 1984 May; 36(3):245-52. PubMed ID: 6432287
[TBL] [Abstract][Full Text] [Related]
4. Statural growth and skeletal maturation in rheumatic prepubertal children treated with a third generation glucocorticoid (deflazacort) versus prednisone. An interim study.
Vignolo M; Milani S; Imbimbo B; Naselli A; Di Battista E; Piaggio G; Leveratto L; Morreale G; Sardella ML; Corsini M
Clin Exp Rheumatol; 1991; 9 Suppl 6():41-5. PubMed ID: 2060177
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort.
Loftus J; Allen R; Hesp R; David J; Reid DM; Wright DJ; Green JR; Reeve J; Ansell BM; Woo PM
Pediatrics; 1991 Sep; 88(3):428-36. PubMed ID: 1881719
[TBL] [Abstract][Full Text] [Related]
6. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders.
Gray RE; Doherty SM; Galloway J; Coulton L; de Broe M; Kanis JA
Arthritis Rheum; 1991 Mar; 34(3):287-95. PubMed ID: 2003854
[TBL] [Abstract][Full Text] [Related]
7. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.
LoCascio V; Ballanti P; Milani S; Bertoldo F; LoCascio C; Zanolin EM; Bonucci E
Calcif Tissue Int; 1998 Mar; 62(3):199-204. PubMed ID: 9501951
[TBL] [Abstract][Full Text] [Related]
8. Effects of prednisone and deflazacort on vertebral bone mass.
Gennari C; Imbimbo B
Calcif Tissue Int; 1985 Dec; 37(6):592-3. PubMed ID: 3937579
[TBL] [Abstract][Full Text] [Related]
9. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids.
Montecucco C; Caporali R; Caprotti P; Caprotti M; Notario A
J Rheumatol; 1992 Dec; 19(12):1895-900. PubMed ID: 1294736
[TBL] [Abstract][Full Text] [Related]
10. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis.
Messina OD; Barreira JC; Zanchetta JR; Maldonado-Cocco JA; Bogado CE; Sebastián ON; Flores D; Riopedre AM; Redondo G; Lázaro A
J Rheumatol; 1992 Oct; 19(10):1520-6. PubMed ID: 1464862
[TBL] [Abstract][Full Text] [Related]
11. Deflazacort. A review of its pharmacological properties and therapeutic efficacy.
Markham A; Bryson HM
Drugs; 1995 Aug; 50(2):317-33. PubMed ID: 8521761
[TBL] [Abstract][Full Text] [Related]
12. Therapy with a new glucocorticoid: effect of deflazacort on linear growth and growth hormone secretion in renal transplantation.
Ferraris JR; Pasqualini T
J Rheumatol Suppl; 1993 Apr; 37():43-6. PubMed ID: 8501752
[TBL] [Abstract][Full Text] [Related]
13. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group.
Ferraris JR; Pasqualini T; Legal S; Sorroche P; Galich AM; Pennisi P; Domene H; Jasper H
Pediatr Nephrol; 2000 Jul; 14(7):682-8. PubMed ID: 10912543
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
[TBL] [Abstract][Full Text] [Related]
15. Effect of therapy with a new glucocorticoid, deflazacort, on linear growth and growth hormone secretion after renal transplantation.
Ferraris JR; Fainstein Day P; Gutman R; Granillo E; Ramirez J; Ruiz S; Pasqualini T
J Pediatr; 1992 Nov; 121(5 Pt 1):809-13. PubMed ID: 1432436
[TBL] [Abstract][Full Text] [Related]
16. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.
Olgaard K; Storm T; van Wowern N; Daugaard H; Egfjord M; Lewin E; Brandi L
Calcif Tissue Int; 1992 Jun; 50(6):490-7. PubMed ID: 1525702
[TBL] [Abstract][Full Text] [Related]
19. Deflazacort in thrombocytopenia: a comparison with prednisone.
Mazzucconi MG; Malagnino F; De Laurentis C; Criscuolo D
Int J Clin Pharmacol Ther Toxicol; 1980 Dec; 18(12):538-42. PubMed ID: 7194867
[TBL] [Abstract][Full Text] [Related]
20. Effect of prednisone on growth and bone mineral content in childhood glomerular disease.
Chesney RW; Mazess RB; Rose P; Jax DK
Am J Dis Child; 1978 Aug; 132(8):768-72. PubMed ID: 685891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
